MADD: First Causal Gene for Quantitative Von Willebrand Disease Discovered
Isabel Bär, PhD candidate at Erasmus MC, shared a proud post on LinkedIn:
”Unraveling the cause of a rare disease by studying an even rarer disease… Who says scientists aren’t creative!
So proud of my amazing colleague Sophie Hordijk, under supervision of Ruben Bierings and Frank Leebeek, for investigating the secretion machinery in a disease affecting only 26 patients worldwide and uncovering insights that bring us closer to solving a major mystery in the most common inherited bleeding disorder globally: Von Willebrand disease.
These findings could help explain why around 20% of Von Willebrand disease patients bleed without carrying mutations in their Von Willebrand factor gene. The identification of MADD as the first causal gene for quantitative Von Willebrand disease is a great example of how rare disease research can unlock answers to broader medical questions.
No wonder that Amazing Erasmus MC picked up on it – truly amazing work, congratulations!
If you want to know why it was necessary to go to 4 different countries (Czech Republic, Germany, Belgium, and the UK) to perform this study, check out the interview.
And if you’re looking for a deeper scientific dive beyond this interview, check the recently published results in Blood!”
To learn more, follow the link.
Read the full article here.
Article: A novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variants
Authors: Sophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N.J. Laan, Georg-Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W.G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben Bierings

Stay updated on the latest scientific advancements in the field of bleeding disorders with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series